653 related articles for article (PubMed ID: 34969393)
21. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
Kurshan A; Snell LB; Prior L; Tam JCH; Graham C; Thangarajah R; Edgeworth JD; Nebbia G; Doores KJ
Oxf Open Immunol; 2023; 4(1):iqac012. PubMed ID: 36844257
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
[TBL] [Abstract][Full Text] [Related]
23. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR; Ku Z; An Z; Carroll SF; Keyt BA; Strohl LM
BioDrugs; 2022 May; 36(3):231-323. PubMed ID: 35476216
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
O'Brien MP; Forleo-Neto E; Musser BJ; Isa F; Chan KC; Sarkar N; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Hou P; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
N Engl J Med; 2021 Sep; 385(13):1184-1195. PubMed ID: 34347950
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
26. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.
Hettle D; Hutchings S; Muir P; Moran E;
Clin Infect Pract; 2022 Nov; 16():100210. PubMed ID: 36405361
[TBL] [Abstract][Full Text] [Related]
27. Immune treatment in COVID-19.
Menéndez R; González P; Latorre A; Méndez R
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):59-63. PubMed ID: 35488829
[TBL] [Abstract][Full Text] [Related]
28. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience.
Cusi MG; Conticini E; Gandolfo C; Anichini G; Savellini GG; Valente S; Franchi F; Scolletta S; Percivalle E; Frediani B
BMC Infect Dis; 2021 Jul; 21(1):630. PubMed ID: 34210259
[TBL] [Abstract][Full Text] [Related]
29. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
30. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Tuccori M; Ferraro S; Convertino I; Cappello E; Valdiserra G; Blandizzi C; Maggi F; Focosi D
MAbs; 2020; 12(1):1854149. PubMed ID: 33319649
[TBL] [Abstract][Full Text] [Related]
31. Development and application of therapeutic antibodies against COVID-19.
Ning L; Abagna HB; Jiang Q; Liu S; Huang J
Int J Biol Sci; 2021; 17(6):1486-1496. PubMed ID: 33907512
[TBL] [Abstract][Full Text] [Related]
32. Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail.
Drouin AC; Theberge MW; Liu SY; Smither AR; Flaherty SM; Zeller M; Geba GP; Reynaud P; Rothwell WB; Luk AP; Tian D; Boisen ML; Branco LM; Andersen KG; Robinson JE; Garry RF; Fusco DN
Viruses; 2021 Jun; 13(7):. PubMed ID: 34201591
[TBL] [Abstract][Full Text] [Related]
33. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
34. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
[TBL] [Abstract][Full Text] [Related]
35. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
Science; 2021 Feb; 371(6531):850-854. PubMed ID: 33495308
[TBL] [Abstract][Full Text] [Related]
36. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy.
Nagai H; Saito M; Adachi E; Sakai-Tagawa Y; Yamayoshi S; Kiso M; Kawamata T; Koga M; Kawaoka Y; Tsutsumi T; Yotsuyanagi H
Jpn J Infect Dis; 2022 Nov; 75(6):608-611. PubMed ID: 35768273
[TBL] [Abstract][Full Text] [Related]
37. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
38. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
39. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity.
Nguyen H; Salkeld J; Agarwal S; Goodman A
Clin Infect Pract; 2021 Nov; 12():100089. PubMed ID: 34426799
[TBL] [Abstract][Full Text] [Related]
40. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]